ALK-Abelló

Board/Management Information • Feb 22, 2016

Copenhagen, 2016-02-22 17:07 CET (GLOBE NEWSWIRE) --

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that as of 22
February 2016, Jens Bager will resign as President and CEO.

The search for a new CEO will be initiated immediately. In the meantime, Steen
Riisgaard will be Chairman of the Board with extended operational
responsibilities, and will in his role act as day-to-day leader of the company.

“The Board assesses that now is a good moment to look for a new CEO. We have
therefore made an agreement with Jens Bager for him to step down from his
position. We will look for a new CEO with relevant experiences and competences
to support the global commercialisation of ALK’s portfolio of evidence-based
products targeting both allergic rhinitis and asthma,” says Steen Riisgaard.

”For 16 years, Jens has led ALK to its present position as world leader within
allergy immunotherapy. ALK has a strong foundation for growth and the company
has reached several important milestones including the approval of the house
dust mite SLIT-tablet ACARIZAX® in 11 European countries and Japan (marketed as
MITICURE™). Moreover, ALK has established a portfolio of promising partnerships
to support its transformation to become a truly global company. We want to
thank Jens for these achievements,” says Steen Riisgaard.

Jens Bager comments on the change: “I take great pride in the company that I
now hand over to a new CEO. All strategic and financial indications are
positive and point in the right direction. That is why the timing of this
change is right in relation to expanding my board career, and I will now pursue
this opportunity.''

There will be no other changes to ALK’s Board of Management consisting of
Henrik Jacobi, EVP Research & Development, Flemming Pedersen, CFO, Søren
Niegel, EVP Commercial Operations and Helle Skov, EVP Product Supply.

                             ALK-Abelló A/S

Audio cast
Tomorrow morning, ALK hosts a conference call at 08.30 a.m. (CET) at which
Chairman of the Board of Director Steen Riisgaard together with members of
Board of Management will answer questions in relation to this announcement. The
call will be audio cast on www.alk-abello.com/investor. Participants in the
conference call are kindly requested to call in before 8.25 a.m. (CET). Danish
participants should call in on tel. 7022 3500 and international participants
should call in on tel. +44 (0) 20 7572 1187 or +1 646 722 4972. Please use the
following participant pin code: 78521931#.

For further information:
Chairman of the Board of Directors and CEO ad interim
Steen Riisgaard, tel. +45 4574 7576

Investor Relations and media:
Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is a world leader in allergy
immunotherapy – a treatment of the underlying cause of allergy. The company has
approximately 1,900 employees with subsidiaries, production facilities and
distributors worldwide. ALK has entered into partnership agreements with MSD
(known as Merck (NYSE: MRK) in the USA and Canada) Torii, Abbott, and Seqirus
to commercialise sublingual allergy immunotherapy tablets in North America,
Japan, Russia, South-East Asia, Australia and New Zealand, respectively. The
company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen.
Find more information at www.alk.net.